Plaintiff
5 cases as plaintiff.
Aerin Medical Inc. is a privately held, venture-backed medical device company founded in 2011 and headquartered in Mountain View, California, with additional offices in Austin, Texas. The company has approximately 101-200 employees. As of December 2024, Aerin Medical raised $32.48 million in Series G funding, co-led by KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation from Ares Capital.
Aerin Medical specializes in innovative, non-invasive treatment solutions for chronic nasal conditions, focusing on nasal airway obstruction (NAO) and chronic rhinitis. Their core products are the VivAer® Stylus for nasal airway obstruction and the RhinAer® Stylus (including the next-generation RhinAer+™ Stylus) for chronic rhinitis. These FDA-cleared devices utilize proprietary temperature-controlled or temperature- and impedance-controlled radiofrequency technology to deliver precise, tissue-sparing treatments that can be performed in a physician's office under local anesthetic.
Aerin Medical Inc. has a patent-litigation posture as a plaintiff, with one tracked case. The company is involved in "Aerin Medical Inc. v. Neurent Medical Ltd. et al.," filed in 2025-06-18 at the Patent Trial and Appeal Board (PTAB) of the USPTO. This indicates that Aerin Medical is asserting its intellectual property, likely challenging the validity of a competitor's patent or defending its own patents against a challenge. Neurent Medical is identified as a competitor by Owler.
Watchlist
Email-only, free, anonymous. We'll notify you when Aerin Medical Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Aerin appeals the PTAB's Final Written Decision in IPR2024-00282 invalidating all challenged claims of the '286 patent. The appeal is pending and consolidated with 25-2099 and 25-2100; no docket entries after October 23, 2025 were available.
This PTAB case was an Inter Partes Review petition filed by Aerin Medical Inc. against Neurent Medical Limited. The petition was not instituted on procedural grounds and was terminated on November 20, 2025.
Aerin Medical Inc. filed an Inter Partes Review (IPR) petition against Neurent Medical Ltd. et al. concerning US patent 11998262. The PTAB issued decisions regarding institution in November and December 2025, ultimately not instituting the review.
Aerin and The Foundry asserted eight patents, including the '077 patent, against Neurent's NEUROMARK nasal-airway treatment device. The case was stayed after PTAB instituted IPR2024-00669 and was consolidated with related matters; counterclaims and motions to dismiss were pending.
Aerin and Foundry sued Neurent in Delaware alleging infringement of eight patents, including the '286 patent, by Neurent's NEUROMARK System. The case was stayed pending IPR final written decisions; after the PTAB invalidated the '286 claims and Aerin appealed, the current docket posture was unconfirmed.